We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma has reached a major milestone in its development in January 2025, with positive topline results from its Phase 3 clinical trial evaluating its microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Enhancing Survival Through Innovative Immune Modulation
We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.
See News
Corporate profile
Press Releases

September 17, 2025: MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update
MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results…
Media Coverage

August 7, 2025: French Tech : Maat Pharma traite les complications de greffe de moelle osseuse – BFM Business (French Only)

July 21, 2025: World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings – Citeline

June 25, 2025: Just the Two of Us: Creating Microbiomes to Fight Cancer, ALS, and More – Inside Precision Medicine
Posters

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial
